Global Cancer Immunotherapy Market Analysis

Cancer Immunotherapy Market Overview

Cancer Immunotherapy Market Size was valued at USD 140.68 Billion in 2023. The Global Cancer Immunotherapy industry is projected to grow from USD 160.34 Billion in 2024 to USD 466.30 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.27% during the forecast period (2024 - 2032). 

Cancer immunotherapy is a cancer treatment that increases the patients' immune system to fight cancer. Many health sectors recently accepted this therapy rather than traditional ones due to its long-term cancer protection. This contains fewer side effects and treats a various range of cancer. The process is used in several types of cancer treatments such as breast cancer, melanoma, prostate cancer, lung cancer, etc. the immunotherapy acts by directing the immune system towards the cancer-specific targets and then activates the immune system to mobilize the target and that triggers a response that is capable of destroying the cancer cells.

In September 2023, Immatics and Moderna strategically partnered to develop Oncology Therapeutics. It also involves assessing the combination of Immatics investigational PRAME203 TCRT with Moderna’s mRNA cancer vaccine, MARTE. Moreover, Shanghai Henlius Biotech Inc. and FBD Biologics Limited formed a strategic alliance in August 2023 that would advance the creation of novel cancer immunotherapies. The market is being driven upward by these events.

By October 2023, FDA will have approved KEYTRUDA (Merck) for use as neoadjuvant therapy prior to surgical resection in resectable NSCLC.

In December 2023, the FDA approved Takeda’s FRUZAQLA (fruquintinib) for use as a line of therapy in patients who have had their metastatic colorectal cancer previously treated.

The National Cancer Institute has released a draft of the National Cancer Plan outlining ways to improve all aspects of cancer care including prevention, early detection, treatment and post-treatment follow-up.

Talvez is approved by FDA for usage in multiple myeloma patient’s refractory to immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies on August 2023.

Very recently only adult patients with BRAF V600E mutation-positive metastatic NSCLC were diagnosed using an FDA-approved test which was introduced into market on October 1st under MEKTOVI (binimetinib) + BRAFTOVI (encorafenib).

China’s National Medical Products Administration has approved durvalumab in combination with gemcitabine plus cisplatin for locally advanced or metastatic biliary tract cancer in adults.

In USA, by mid-2023, many therapeutic vaccines have had regulatory process through: talimogene laherparepvec (an oncolytic viral agent), Bacillus Calmette Guerin (BCG stands for), bacillus calmette-guerin(BCG) and Pulpuecel-T also known as Provenge which is an adoptive cellular therapy used to treat castration-resistant prostate cancer.

Covid-19 analysis

COVID 19 has Impacted the healthcare sector positively. In the first half of the spread, the cancer immunotherapy market was reduced due to the continuous COVID 19 patients increases and the lockdown improvement and ban order on travel. The cancer patients rate was getting high, but the whole attention was on the spread of the virus and was trying to fight the novel coronavirus. Due to that, many cancer treatments were postponed impacting the market value. With the betterment of the condition, the treatment procedure for cancer patients resumed again as it is necessary to give proper treatment to cancer patients. Although everything was resumed due to the virus spread, the market experience loss as the unavailability of doctors, social distancing and less activity in medical except for the covid patients was limited. The market has been growing recently and is expected to get to its real growth, and cancer patients get treatment as soon as possible.

Cancer Immunotherapy Market Trends

• Key Drivers

Each driving factor has impacted Cancer Immunotherapy Market Value. The major growth factors of the market are various, and they help the market gain marketplace during the forecast period. The growing occurrence of cancer due to bad lifestyle and the young generation getting dependent on the internet and sitting idle at home is driving the market's growth. Growing cancer patients in almost all regions are impacting the market growth and forming new ways for the market. Rising research and development by the pharmaceutical and the government regarding cancer treatment are also boosting the market. Continuous technological development in the healthcare sectors for patients' suitability is accelerating the Cancer Immunotherapy Market Outlook. High efficiency in immunotherapy rather than other treatments are also growth factors.

• Market Challenges

Rising competition in product development is forming challenges for market growth. Lack of skilled professionals to carry out the process and less information and awareness also impact the market and create challenges decreasing market growth. There are several types of cancer, so it becomes complicated to develop a new drug with high quality, which obstructs the market share.

• Market Opportunities

The rising adaptation of new therapeutics for cancer treatment and increasing implementation in the healthcare sectors are creating new opportunities for the market and market players. The growing focus of the public organizations on researching diseases and forming new development activities towards immunotherapy is forming abundant opportunities for the Cancer Immunotherapy Market.

• Market Restraints

The main restrain of the market is much cancer shows resistance to chemotherapy and radiation therapy. In addition to this, the high cost of cancer treatment in several health sectors is hindering market growth. Many people are unaware of immunotherapy, and less information regarding cancer immunobiology limits the cancer immunotherapy market.

Cumulative Evaluation Of The Market

The market shows ample factors that will help further grow the cancer immunotherapy market. Covid 19 has positively affected the cancer immune therapy market  Size and impacted the market revenue. The prominent factors present in the markets also impact the market size. Different drivers and opportunities are opening several successful doors for the market. Whereas the restrains and the challenges affect the revenue of the market. With the rising cancer population and the awareness programs, people are getting more diagnosed than before, which improves the market situation. The Cancer Immunotherapy Market Trends are also followed while depicting the worldwide market situation.

Cancer Immunotherapy Market segment Insights

• 
  

  Cancer Immunotherapy type Insights

  
  

Based on the segment type therapy, the cancer immunotherapy market is classified into Monoclonal Antibodies, Adoptive Cell Transfer and others. Monoclonal antibodies registered high CAGR in 2020 due to the rising usage of monoclonal antibodies for cancer immunotherapy. It is used because they exhibit different properties where the immune system can be modulated and activate the molecules targeted on the immune system.

• 
  

  Cancer Immunotherapy application Insights

  
  

The application is analyzed by Lung Cancer, Childhood Cancer and others. Among all the segment net, the lung cancer segment dominated the market and held the largest Cancer Immunotherapy Market Share in 2020. It is getting popular day by day due to the high number of lung cancer globally and the continuous surge in the awareness programs regarding the information about the need for early therapies of lung cancer.

• 
  

  Cancer Immunotherapy end-user Insights

  
  

The Cancer Immunotherapy Market Forecast shows Hospitals and Clinics, and others are the variables by the segment end-user. Hospital is expected to register high market CAGR  and dominate the cancer immunotherapy market in 2020. As the extensive use of cancer immunotherapy increased in the hospital, the segment showed the highest growth rate. Rising preference towards hospitals is expected to propel the growth segment in the forthcoming years. The segment is estimated to register a growth rate of 14.7% in the forecast period.

Regional analysis

The cancer immunotherapy market is studied in North America, Asia Pacific, Europe, Latin America, the middle east and Africa. In 2020, North America accounted for the largest market share due to the rise of healthcare expenditure. The rising focus on maintaining the best healthcare in the sector and the increasing number of cancer patients worldwide is boosting the market in that region. The presence of high-end medical facilities is one of the growth factors in the region. Asia pacific is also showcasing a high growth rate due to the increase in the per capita income, continuous improvement done by governed of the healthcare system and infrastructure and rise in healthcare expenditure are main factors of the market growth in the Asia region. Rising incidence and rising economy in Europe regions will propel the market in the region. All the mentioned regions and other regions present in the market will form new opportunities for market growth. In the coming years, the market will register a high CAGR.

Competitive Intensity Within The Industry 

several prominent players are present in the cancer immunotherapy market. Some new market players are also interested in investing in the future depending on the Cancer Immunotherapy Market Growth. New Market development is based on the strategies carried out by the market players. The details of the competitor are involved in the report. Other details taken into account by the competitors are market condition, production of the market, the dominance of the market in the global place, revenue, finance, investment and others. The key players are estimated to improve the market value in strategically made ways. The competitive landscape between the different market players will positively impact the market. The major key payers that accumulate the market with the growth are

• Merck & Co., Inc.,


• Novartis International AG


• Seattle Genetics


• Bristol-Myers Squibb


• F. Hoffmann-La Roche AG


• GlaxoSmithKline Plc., Amgen Inc.


• Eli Lilly and Company


• Celgene Corporation, , Inc.


• Spectrum Pharmaceuticals, Inc.

Recent development 

• Bristol Myers Squibb announced that united states regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer.


• The united food and drug Administration approved realtime from a class known as LAG-3 inhibitors(lymphocyte-activation gene 3) for use with bristol's blockbuster immunotherapy opdivo as an initial treatment for advanced melanoma.

Report Overview

The cancer immunotherapy market suggests several new variations and strategies that would have an accelerating impact on the market. In the report, several primary and secondary research techniques are included to provide a clear view. The report builds strong capabilities in data collection, interpretation and analysis of data. Many quantitative and qualitative information regarding the market is also included in the report to highlight the current scenario of the Cancer Immunotherapy Market Size. The report consists of market segmentation that increases market share, regions where the market players are present, current developments, and processes to take the market to its peak in the global market.

Cancer Immunotherapy Market Segmentation

Cancer Immunotherapy Type Outlook

•  Monoclonal Antibodies,


•  Adoptive Cell Transfer


•  others

Cancer Immunotherapy Application Outlook

•  Lung Cancer


•  Childhood Cancer


•  Other

Cancer Immunotherapy end-user Outlook

• Hospitals, Clinics


• Others